

- ◆ **Orders received** rose by 11% to SEK 9,657 million (8,668)
- ◆ **Net sales** rose by 13% to SEK 9,006 million (7,992)
- ◆ **Profit before tax** amounted to SEK 941 million (908)
- ◆ **Net profit** amounted to SEK 687 million (654)
- ◆ **Earnings per share** totalled SEK 3.38 (3.19)
- ◆ **Continued positive earnings outlook**

Third quarter 2006

Orders received

Demand for the Group's products remains favourable and the trend for orders received continues to be positive. Orders received organically increased 6.8% during the quarter. Accordingly, the organic increase amounts to 7.8% for the first nine months of the year. Adjusted for the major orders booked in Extended Care's Canadian operations during the first quarters of 2005 and 2006, the organic growth in orders received amounted to 10%.

In Medical Systems, orders received organically increased by 8.3% during the quarter and were particularly favourable for Surgical Workplaces. Growth in both Western Europe and the US was highly favourable.

Infection Control's orders received increased at a somewhat slower pace during the quarter and, organically, amounted to 4.1%. The cancellation of a major Life Science order in the US resulted in a declining trend in orders received in the North American region during the quarter.

For Extended Care, orders received organically increased by a full 7.6%. Orders received in the US remained highly favourable.

Results

Consolidated profit before tax rose by 8% compared with the corresponding period in the preceding year and amounted to SEK 315 million (291).

Medical Systems' profit continues to develop well. Operating profit increased by 9.5% and the operating margin amounted to a strong 16.2% for the quarter. All divisions within the business area performed well.

Within Infection Control, profit was somewhat lower than in the corresponding period of 2005. The lower gross margin during the period is primarily attributable to temporary changes in product mix.

Extended Care's profit increased by 8% during the quarter and the operating margin was on the same level as in the preceding year. Costs for production transfers in patient-handling operations declined during the quarter in conjunction

with completion of the closure of the Gloucester unit. A planned divestment of the production plant in Gloucester generated a capital gain that offsets the nonrecurring costs related to the wound-care operations. The Group's operational cash flow continues to develop well and amounted to SEK 383 million during the quarter (446). The operational cash flow for the nine-month period amounted to SEK 1,664 million (1,356).

Outlook

The status of demand for the Group's products remains favourable. The volume trend in North America and the developing markets is on a high and stable level, while demand is gradually improving in Western Europe. The Group's order backlog remains at a favourable level compared with the corresponding time in 2005.

Medical Systems anticipates a continued favourable volume trend during the year as a result of good demand, product launches completed and an expanded market organisation. Profit in the Cardiopulmonary Division is improving steadily as a result of completed measures.

The year 2006 is characterised by a large number of future-oriented investments. The market and sales organisations in Asia, Latin America and Eastern Europe have been strengthened during the year, as has the North American sales organisation. Product-development measures were extended prior to planned product launches in 2007 and 2008 in Critical Care and Cardiopulmonary. In parallel with these measures, investments are being made to build new and cost-efficient production capacity in Turkey and China.

Similar to Medical Systems, Infection Control is expected to have a continued positive volume trend during the current year. The business area's North American operations continue to develop in a positive direction in terms of both profit and volume growth in the wake of measures implemented. Similar to Medical Systems, a large number of measures are being implemented in preparation for the future, particularly regarding the expansion of the sales organisation in China, Latin America, India and Japan. Within the supply chain area, production in South Africa has been relocated to Sweden, while investments were made to achieve a more efficient logistics structure. The integration of La Calhène will essentially be completed during the year, while La Calhène contributes to a gradual improvement in the business area's profit.

As a result of the large deliveries made to the healthcare authority in Ontario, Canada, in 2005, the volume increase for Extended Care is expected to be modest for this year. Deliveries of patient-handling equipment to the US have normalised since the beginning of the year. The restructuring costs relating to the change made in Extended Care's production structure for patient-handling products will be charged to the current year's profits in an amount of SEK 45 million and are expected to lead to cost-savings of SEK 50 million from 2007 and SEK 70 million from 2008.

In summary, it is assessed that the volume outlook remains generally favourable. The numerous measures being implemented in the Group regarding the market organisation, product development, new production structure and plant consolidation will strengthen the Group's profitability in the long term and lead to good profit growth in the next year.

The Group has not substantially changed its view of the current year's earnings outlook since the publication of the most recent report. The somewhat weaker

trend in Extended Care is offset by continued favourable development for Medical Systems.

Business area Medical Systems

Market development

Orders received per market	2006	2005	Change adjusted for	2006	2005	Change adjusted for
	Q 3	Q 3	curr.flucs.&corp.acqs.	9 Mon	9 Mon	curr.flucs.&corp.acqs.
Western Europe	675.0	612.4	11.8%	2,080.6	1,934.5	6.7%
USA and Canada	293.6	265.8	16.5%	912.3	744.3	18.7%
Asia and Australia	210.8	239.3	-8.0%	631.0	685.2	-7.9%
Rest of the world	147.5	144.1	5.4%	625.9	322.4	89.9%
Business area total	1,326.9	1,261.6	8.3%	4,249.8	3,686.4	13.7%

The trend for orders received by the business area remained strong and increased organically by 8.3% during the quarter. Orders received in Western Europe were particularly favourable, with a rise of 11.8%. All regions, except the UK, reported favourable growth. Volume growth was particularly strong in the German-speaking markets, southern Europe and in Scandinavia. The North American market also recorded very strong growth in Surgical Workplaces and Critical Care. The trend in developing markets was mixed, with the decline in the markets in Southeast Asia and Eastern Europe, while the markets in Latin America performed well.

Results

	2006	2005	Change	2006	2005	Change	2005
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	1,283.3	1,256.5	2.1%	3,861.5	3,470.5	11.3%	5,109.2
<i>adjusted for currency flucs.& corp.acqs</i>			4.8%			9.7%	
Gross profit	631.6	606.6	4.1%	1,913.9	1,688.6	13.3%	2,486.3
Gross margin %	49.2%	48.3%	0.9%	49.6%	48.7%	0.9%	48.7%
Operating cost, SEK million	-424.3	-417.3	1.7%	-1,350.0	-1,236.5	9.2%	-1,704.9
EBITA	208.8	190.7	9.5%	568.4	456.1	24.6%	787.3
EBITA margin %	16.3%	15.2%	1.1%	14.7%	13.1%	16%	15.4%
EBIT	207.3	189.3	9.5%	563.9	452.1	24.7%	781.4
EBIT margin %	16.2%	15.1%	1.1%	14.6%	13.0%	16%	15.3%

Operating profit rose by 9.5% during the quarter and the operating margin amounted to a full 16.2% in the seasonally weak third quarter. The gross margin remains at a favourable level due to the efficiency measures implemented in Cardiopulmonary and a good product mix.

Activities

Product development and product launches

The major product-development projects currently being conducted in the Critical Care division are proceeding according to plan. NAVA, which is a completely new ventilator technology linked to the division's existing Servo product platform, will be launched during the first six months of 2007. Through NAVA, considerably improved synchronisation between the patient's own spontaneous breathing and

the ventilator's breathing support is achieved. Studies at a number of hospitals have shown highly promising results. NAVA is based on the principle of using a catheter to capture signals from the brain, which controls the patient's breathing, thereby enabling better reactivity in the ventilator.

Work to produce a new family of anaesthesia machines is also proceeding according to plan. It is expected that it will be possible to deliver the first products at the beginning of 2008. The new anaesthesia program is expected to be highly competitive in terms of cost structure and performance. The market for anaesthesia products is expected to amount to about SEK 5,500 million and the ambition is to become a significant market player.

Ambitious product-development work is also being conducted in Cardiopulmonary. A new family of innovative oxygenators, based on Quadrox technology, will be rolled out in 2007-2008.

New production structure within Cardiopulmonary

As previously announced, Cardiopulmonary is currently working to enhance the efficiency of its production of consumables. The production of the personnel-intensive consumables, such as catheter production and "custom tubing packs" will be relocated to Turkey, where a new plant is being constructed. Production in Turkey will commence in Q1 2007. In parallel with the build-up of local production in Turkey, increased coordination of production will occur between the remaining, more mechanised production plants in Germany.

Local production in China

Medical Systems, similar to Infection Control, intends to establish local production in China. Production will initially focus on production of ceiling service units and surgical lights. Effective 2008, there is also an ambition to produce low-end surgical tables locally in China. The initiative is aimed at increasing market penetration in the growing Chinese market, but also at strengthening the business area's competitiveness in markets outside China. As a result of the above, the Group's existing production unit in Suzhou, outside Shanghai, will be expanded in 2007.

Acquisition of Medical Systems in Brazil

At the end of the period, the business area completed the acquisition of the Brazilian company Medical Systems, which produces and markets consumables for open heart surgery. The company has sales of approximately SEK 25 million and has 22 employees. There is a large and growing market for open-heart surgery in Brazil, representing slightly more than 5% of the global market. Cardiopulmonary anticipates being able to capture a significant share of the existing market in the next few years. Medical Systems is consolidated within the Group effective October 2006.

Acquisition of OTY GmbH in Germany

The market for telemedicine products is growing strongly, particularly in the operating theatre, where surgeons and personnel need rapid access to such patient data as X-ray images and patient notes. The storage of large amounts of patient data that is generated during an operation is another key telemedicine component that requires rational and effective management. OTY has built up strong expertise and a product portfolio in the telemedicine area and has demonstrated extremely rapid growth in recent years. Medical Systems assesses that OTY products, within the framework for Surgical Workplaces' global market organisation, will be able to gain rapid coverage. OTY is consolidated in the Group from September 2006. OTY has sales of SEK 20 million with 14 employees.

Business area Infection Control

Market development

Orders received per market	2006	2005	Change adjusted for	2006	2005	Change adjusted for
	Q 3	Q 3	curr.flucs.&corp.acqs.	9 Mon	9 Mon	curr.flucs.&corp.acqs.
Western Europe	500.8	446.6	13.5%	1,543.2	1,288.5	10.8%
USA and Canada	301.5	350.8	-8.7%	1,056.8	951.4	0.1%
Asia and Australia	101.7	84.1	26.0%	341.0	292.5	14.5%
Rest of the world	52.4	75.1	-22.7%	158.0	147.1	11.2%
Business area total	956.4	956.6	4.1%	3,099.0	2,679.5	7.4%

Orders received increased organically by 4.1% compared with the third quarter of 2005.

The volume trend in Western Europe was particularly favourable with good growth in the UK, southern Europe and in the German-speaking markets. In Scandinavia, orders received declined, while the trend in the Benelux region was on the same level as in 2005.

In North America, orders received declined primarily in the Life Science business in the US, which is more volatile in character and was charged with a major cancellation. The order trend in terms of hospital customers remained positive. The volume trend for Infection Control in developing markets remained mixed. In Southeast Asia and China, the trend remained positive, while there was a weakening in orders received from the regions in Eastern Europe and Latin America.

Results

	2006	2005	Change	2006	2005	Change	2005
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	890.2	804.7	10.6%	2,839.4	2,352.4	20.7%	3,745.1
<i>adjusted for currency flucs. & corp.acqs</i>			14.6%			118%	
Gross profit	301.1	291.1	3.4%	1,049.0	894.2	17.3%	1,429.2
Gross margin %	33.8%	36.2%	-2.4%	36.9%	38.0%	-1.1%	38.2%
Operating cost, SEK million	-238.2	-225.1	5.8%	-791.1	-654.6	20.9%	-917.8
EBITA	66.6	68.6	-2.9%	269.3	242.2	11.2%	517.9
EBITA margin %	7.5%	8.5%	-1.0%	9.5%	10.3%	-0.8%	13.8%
EBIT	62.9	66.0	-4.7%	257.9	239.6	7.6%	511.4
EBIT margin %	7.1%	8.2%	-1.1%	9.1%	10.2%	-1.1%	13.7%

Infection Control's operating profit for the quarter was somewhat lower than in the year-earlier period, primarily as a result of a lower gross margin and increased costs due to the implementation of measures intended to improve future profitability. The lower gross margin is attributable to product mix changes of a temporary nature. The gross margin is expected to strengthen during the remainder of the year.

Activities

Logistics project

The logistics project initiated some time ago is proceeding according to plan. Spare-parts handling has been concentrated in Puurs in Belgium and has been managed by a third-party operator since the end of 2005. The rollout of the joint IT platform that will enable further efficiency enhancements in invoicing, order and

shipping procedures is in progress. When fully implemented, it is expected that the project will result in annual savings of about SEK 50 million.

La Cahlène

The integration program initiated shortly after the acquisition of the French company La Cahlène is largely completed. La Cahlène's market organisation is now fully integrated in Getinge's existing Life Science division. Remaining changes and improvements mainly relate to the production unit in Vendôme, France, and are expected to be completed during the first quarter of 2007.

Increased production in China

The expansion of the locally manufactured product program in China to also include disinfectors is proceeding to plan. The first deliveries of disinfectors are scheduled to take place during the fourth quarter of this year.

Outsourcing of sterilisation centres in the UK

The UK NHS' (National Health Service) plans to establish a number of supercentres for the production and distribution of sterile instruments to hospitals on an outsourcing basis are advancing, but at a slow pace. Infection Control anticipates being able to book orders during this year.

Business area Extended Care

Market development

Orders received per market	2006 Q 3	2005 Q 3	Change adjusted for curr.flucs.&corp.acqs.	2006 9 Mon	2005 9 Mon	Change adjusted for curr.flucs.&corp.acqs.
Western Europe	416.4	414.6	2.0%	1,358.4	1,284.8	4.7%
USA and Canada	261.5	230.2	18.7%	845.4	893.8	-10.3%
Asia and Australia	21.7	23.4	-1.7%	73.6	77.3	-4.9%
Rest of the world	4.8	4.3	10.0%	15.5	12.6	17.2%
Business area total	704.4	672.5	7.6%	2,292.9	2,268.5	-1.4%

Orders received increased organically by 7.6% during the period. Volume growth in Western Europe developed weakly during the quarter, primarily as a result of a decline in the UK. Other regions in Western Europe demonstrated favourable growth, including southern Europe, Scandinavia and German-speaking countries. Volume growth remained very favourable in North America, primarily in terms of the US market, where ceiling hoist sales account for a considerable portion of the improvement. In the developing markets, orders received overall were on the same level as in 2005.

Results

	2006	2005	Change	2006	2005	Change	2005
	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales, SEK million	709.6	656.3	8.1%	2,290.1	2,136.6	7.2%	2,982.1
<i>adjusted for currency flucs.& corp.acqs</i>			11.3%			4.5%	
Gross profit	325.0	302.0	7.6%	1,029.5	1,007.7	2.2%	1,396.9
Gross margin %	45.8%	46.0%	-0.2%	45.0%	47.2%	-2.2%	46.8%
Operating cost, SEK million	-227.7	-212.3	7.3%	-762.4	-639.7	19.2%	-891.1
EBITA	101.1	93.8	7.8%	278.7	379.4	-26.5%	521.6
EBITA margin %	14.2%	14.3%	-0.1%	12.2%	17.8%	-5.6%	17.5%
EBIT	97.3	89.7	8.5%	267.1	368.0	-27.4%	505.8
EBIT margin %	13.7%	13.7%	0.0%	11.7%	17.2%	-5.5%	17.0%

The business area's profit for the period rose by 8,5% compared with the corresponding quarter in 2005. The operating margin was on the same level as the preceding year. During the quarter, a planned divestment of the production plant in Gloucester generated a capital gain that offset the nonrecurring costs for the impairment of accounts receivable in the American wound-care operations. The gross margin improved toward the end of the quarter and was an effect of the Gloucester unit being closed according to plan during the quarter.

Activities

Restructuring of patient-handling production

The restructuring program that was initiated at the beginning of this year and is aimed at concentrating all manufacturing of patient-handling products to Extended Care's production units in Belgium and Canada was completed during the quarter. The costs of the program amount to SEK 45 million. Cost-savings from the implemented program are expected to amount to SEK 50 million in 2007, increasing to SEK 70 million annually from 2008. The capital gain, included in Other income, from the divestment according to plan of the production plant in Gloucester amounted to SEK 34 million.

Impairment of accounts receivable in the American wound-care operations.

As announced in a separate press release, Extended Care recognized an impairment loss in accounts receivable in a value of SEK 28 million, included in Selling expenses, attributable to the 2003-2005 fiscal years in the business area's wound-care operations.

International expansion

Extended Care has a highly significant share of its existing sales concentrated in the developed markets of Western Europe and North America. In an effort to strengthen the business area's positions in the developing markets that will be important in the long term and in the Japanese market, an international division has been formed under new management. This division will work to develop the existing distributor network, but also ensure that Extended Care selectively establishes its own new sales channels in markets assessed as having major growth potential.

Other information

Nomination Committee for AGM 2007

In accordance with a decision by Getinge AB's Annual General Meeting 2005, the Nomination Committee comprises Getinge's Chairman, representatives of the five largest shareholders at 31 August 2006, and a representative of the smaller shareholders.

Accordingly, Getinge's Nomination Committee for the Annual General Meeting in 2007 comprises: Carl Bennet, Carl Bennet AB; Marianne Nilsson, Robur; Björn Franzon, Fjärde AP Fonden; Joachim Spetz, Handelsbanken; Cecilia Lager SEB fonder and Olle Törnblom, representative of the smaller shareholders.

Shareholders wishing to submit proposals to Getinge's Nomination Committee 2007 can contact the Nomination Committee by e-mail at valberedningen@getinge.com or by letter to: Getinge AB, Attention: Valberedningen, Box 69, 310 44 GETINGE.

Annual General Meeting

Getinge AB's Annual General Meeting will be held on 19 April 2007, at 4:00 p.m., in the Kongresshallen, Hotell Tylösand, Halmstad, Sweden. Shareholders who wish to have a matter addressed at the Meeting on 19 April 2007, can submit proposals to Getinge's Chairman by e-mail to arenden.bolagsstamma07@getinge.com or by letter to: Getinge AB Attn. Bolagsstämмоärende, Box 69, 310 44 GETINGE. To be certain of inclusion in the notification of the Meeting and, accordingly, in the Meeting agenda, the proposals must reach the company not later than Thursday, 1 March 2007.

Accounting

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting. The same accounting principles and methods of calculation were used in this interim report as in the most recent annual report.

Future-oriented information

This report contains future-oriented information based on the current expectations of Getinge's Group management. Although the management deems that the expectations presented by such future-oriented information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the future-oriented information due to such factors as changed conditions regarding finance, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.

Next report

The next report from the Getinge Group (Year-end Report 2006) will be published on 24 January 2007.

Teleconference

A teleconference will be held today at 3:00 p.m. Swedish time. To participate, please call:

from Sweden 08-505 20110, password: Getinge

from outside Sweden +44(0)20 7162 0025, password: Getinge

A recorded version of the conference will be available for five working days on the following numbers:

Sweden: +46 (0) 850520333, access code: 722989

UK: +44 (0)20 7031 4064, access code: 722989

Getinge 18 October 2006

Johan Malmquist
President

Getinge AB
Box 69, 310 44 Getinge
Telephone +46 (0)35 15 55 00. Fax +46 (0)35 549 52
email info@getinge.com
Company reg. No. 556408-5032
www.getinge.com

Income statement

	2006	2005	Change	2006	2005	Change	2005
SEK million	Q 3	Q 3		9 Mon	9 Mon		FY
Net sales	2,883.2	2,727.4	5.7%	9,005.7	7,991.6	12.7%	11,880.4
Cost of goods sold ⁴	-1,625.4	-1,524.4	6.6%	-5,009.1	-4,391.8	14.1%	-6,554.9
Gross profit	1,257.8	1,203.0	4.6%	3,996.6	3,599.8	11.0%	5,325.5
Gross margin	43.6%	44.1%	-0.5%	44.4%	45.0%	-0.6%	44.8%
Selling expenses ⁴	-603.7	-509.7	18.4%	-1,827.5	-1,563.1	16.9%	-2,205.3
Administrative expenses ⁴	-273.1	-281.4	-2.9%	-853.7	-775.5	10.1%	-1,055.5
Research & development costs ¹⁾	-58.4	-59.8	-2.3%	-211.3	-193.4	9.3%	-257.1
Other operating income and expenses	44.9	-5.5	-916.4%	-7.9	-5.2	519%	-4.8
Operating profit ²⁾	367.5	346.6	6.0%	1,096.2	1,062.6	3.2%	1,802.8
Operating margin	12.7%	12.7%	0.0%	12.2%	13.3%	-1.1%	15.2%
Financial net	-52.9	-55.4		-155.7	-154.3		-201.4
Profit before tax	314.6	291.2	8.0%	940.5	908.3	3.5%	1,601.4
Taxes	-84.9	-81.5		-253.9	-254.3		-451.7
Net profit	229.7	209.7	9.5%	686.6	654.0	5.0%	1,149.7
Attributable to:							
Parent company's shareholders	230.7	207.9		682.7	644.5		1,138.4
Minority interest	-1.0	1.8		3.9	9.5		11.3
Net profit	229.7	209.7		686.6	654.0		1,149.7
Earnings per share, SEK ³⁾	1.14	1.03	13.1%	3.38	3.19	6.0%	5.64

1) Development costs totalling SEK 128.2 (109.8) million have been capitalised during the year, of which 46.2 (39.6) million were capitalised during the quarter.

2) Operating profit is charged with

— amort. intangibles	-19.5	-15.2	-57.8	-37.2	-54.1
— depr. on other fixed assets	-60.6	-74.2	-194.6	-204.2	-274.6
	-80.1	-89.4	-252.4	-241.4	-328.7

3) There are no dilutions

4) Due to reclassification of certain costs, some transfer have been made in the comparison from cost of goods sold to operating costs.

Quarterly results

	2004	2004	2005	2005	2005	2005	2006	2006	2006
SEK million	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3
Net sales	2,332.5	3,476.6	2,525.2	2,739.0	2,727.4	3,888.8	2,974.8	3,147.7	2,883.2
Cost of goods sold	-1,274.0	-1,981.1	-1,348.7	-1,518.7	-1,524.4	-2,163.1	-1,651.3	-1,732.4	-1,625.4
Gross profit	1,058.5	1,495.5	1,176.5	1,220.3	1,203.0	1,725.7	1,323.5	1,415.3	1,257.8
Operating cost	-753.7	-815.0	-814.1	-866.7	-856.4	-985.5	-1,012.7	-997.4	-890.3
Operating profit	304.8	680.5	362.4	353.6	346.6	740.2	310.8	417.9	367.5
Financial net	-49.0	-46.9	-49.5	-49.4	-55.4	-47.1	-49.2	-53.6	-52.9
Profit before tax	255.8	633.6	312.9	304.2	291.2	693.1	261.6	364.3	314.6
Taxes	-61.0	-170.4	-87.6	-85.2	-81.5	-197.4	-70.6	-98.4	-84.9
Profit after tax	194.8	463.2	225.3	219.0	209.7	495.7	191.0	265.9	229.7

Balance sheet

	2006	2005	2005
Assets SEK million	30 Sep	30 Sep	31 Dec
Intangible fixed assets	5,609.0	5,355.3	5,530.3
Tangible fixed assets	1,366.9	1,488.3	1,497.8
Financial assets	798.4	666.9	649.8
Stock-in-trade	2,353.5	2,455.6	2,156.6
Current receivables	3,628.4	3,265.3	4,015.2
Cash and cash equivalents	682.6	849.7	683.6
Total assets	14,438.8	14,081.1	14,533.3
Shareholders' equity & Liabilities			
Shareholders' equity	5,539.9	4,807.4	5,381.3
Long-term liabilities	5,616.7	6,282.9	6,159.2
Current liabilities	3,282.2	2,990.8	2,992.8
Total Equity & Liabilities	14,438.8	14,081.1	14,533.3

Cash flow statement

SEK million	2006 Q 3	2005 Q 3	2006 9 Mon	2005 9 Mon	2005 FY
<i>Current activities</i>					
Operating profit	367.6	346.6	1,096.3	1,062.6	1,802.8
Adjustment for items not included in cash flow	42.2	93.8	200.1	248.1	329.1
Financial items	-52.9	-55.4	-155.7	-154.3	-196.5
Taxes paid	-65.8	-123.5	-307.9	-360.1	-475.9
Cash flow before changes in working capital	291.1	261.5	832.8	796.3	1,459.5
Changes in working capital					
Stock-in-trade	-46.5	-144.0	-291.9	-464.6	-130.4
Rental equipment	-2.8	-5.5	-1.7	-17.8	-13.7
Current receivables	-139.7	75.3	309.8	542.7	-125.7
Current operating liabilities	161.9	79.4	352.1	-14.9	3.7
Restructuring reserves, utilised	-0.4	-0.8	-0.6	-21.5	-24.1
Cash flow from operations	263.6	265.9	1,200.5	820.2	1,169.3
<i>Investments</i>					
Acquisition of subsidiaries	-242.8	-0.8	-239.1	-127.2	-265.4
Investments in intangible fixed assets	-48.9	-45.5	-132.6	-118.0	-166.9
Investments in tangible fixed assets	-86.9	-59.6	-204.8	-169.0	-235.7
Disposal of tangible fixed assets	57.8	1.4	151.7	4.4	10.8
Cash flow from investments	-320.8	-104.5	-424.8	-409.8	-657.2
<i>Financial activities</i>					
Change in interest-bearing debt	-232.4	13.1	-379.1	403.6	142.6
Change in long-term receivables	29.3	7.6	-90.5	116.1	108.2
Minority redemption	54.5		54.5		
Dividend paid	-1.7		-405.4	-333.1	-333.1
Cash flow from financial activities	-150.3	20.7	-820.5	186.6	-82.3
Cash flow for the period	-207.5	182.1	-44.8	597.0	429.8
Cash and cash equivalents at begin of the year	942.4	658.2	683.6	484.9	484.9
Translation differences	-52.3	9.4	43.8	-232.2	-231.1
Cash and cash equivalents at end of the period	682.6	849.7	682.6	849.7	683.6

Operating cash flow statement

SEK million	2006 Q 3	2005 Q 3	2006 9 Mon	2005 9 Mon	2005 FY
Business activities					
Operating profit	367.5	346.6	1,096.2	1,062.6	1,802.8
Adjustment for items not included in cash flow	42.1	93.8	200.0	248.1	329.1
	409.6	440.4	1,296.2	1,310.7	2,131.9
Changes in operating capital					
Stock-in-trade	-46.5	-144.0	-291.9	-464.6	-130.4
Rental equipment	-2.8	-5.5	-1.7	-17.8	-13.7
Current receivables	-139.7	75.3	309.8	542.7	-125.7
Current liabilities	161.9	79.4	352.1	-14.9	3.7
Operating cash flow	382.5	445.6	1,664.5	1,356.1	1,865.8

Net interest-bearing debt

SEK million	2006 30 Sep	2005 30 Sep	2005 31 Dec
Debt to credit institutions	3,702.6	4,365.3	4,097.4
Provisions for pensions, interest-bearing	1,672.3	1,567.9	1,690.4
Less liquid funds	-682.6	-849.7	-683.6
Net interest-bearing debt	4,692.3	5,083.5	5,104.2

Changes to shareholders' equity

SEK million	2006 30 Sep	2005 30 Sep	2005 31 Dec
Shareholders' equity – opening balance	5,381.3	4,269.6	4,269.6
Effect of adopting to IFRS on opening balance		97.0	97.0
Shareholders' equity - opening balance according to new principle	5,381.3	4,366.6	4,366.6
Dividend distributed	-403.7	-333.1	-333.1
Dividend to minority	-1.7	–	–
Change of reserve hedge accounting	99.3	-190.4	-184.5
Change of minority	-54.8	–	–
Translation differences	-167.1	310.3	382.6
Net profit	686.6	654.0	1,149.7
Shareholders' equity – closing balance	5,539.9	4,807.4	5,381.3
Attributable to:			
Parent company's shareholders	5,520.0	4,746.8	5,307.4
Minority interest	19.9	60.6	73.9
Total shareholders' equity	5,539.9	4,807.4	5,381.3

Key figures

	2006	2005	Change	2006	2005	Change	2005
	Q 3	Q 3		9 Mon	9 Mon		FY
Orders received, SEK million	2,987.7	2,900.9	3.0%	9,656.6	8,667.7	11.4%	12,225.0
adjusted for currency flucs.& corp.acqs			6.8%			7.8%	
Net sales, SEK million	2,883.2	2,727.4	5.7%	9,005.7	7,991.6	12.7%	11,880.4
adjusted for currency flucs.& corp.acqs			9.2%			8.9%	
Earnings per share after full tax, SEK	1.14	1.03	13.1%	3.38	3.19	6.0%	5.64
Nmb of shares, thousands	201,874	201,874		201,874	201,874		201,874
Operating capital, SEK million				10,132.9	8,958.4	13.1%	9,571.0
Return on operating capital, per cent				18.0%	18.6%	-0.6%	18.5%
Return on equity, per cent				22.2%	25.2%	-3.0%	24.3%
Net debt/equity ratio, multiple				0.85	1.06	-0.21	0.95
Interest cover, multiple				8.7	8.0	0.7	8.3
Equity/assets ratio, per cent				38.4%	34.1%	4.3%	37.0%
Number of employees at the period's end				7,428	7,252		7,362

Companies acquired and divested in 2006

BHM Medical Inc

In July 2006, the remaining 25% of shares in the Canadian company BHM Medical Inc were acquired for approximately SEK 198 million. Goodwill in conjunction with the acquisition amount to approximately SEK 64 million.

OTY GmbH

In August 2006, the Getinge Group acquired 60% of the shares in the company OTY GmbH. OTY is an innovative and rapidly growing company in the field of telemedicine, focusing on products and solutions for hospitals' IT infrastructure, with emphasis on the operating theatre. At the time of acquisition, the company's assets amounted to SEK 9 million and liabilities to SEK 6 million. The agreed purchase price totalled approximately SEK 44 million. The study of the distribution of the purchase price has not yet been completed. OTY is consolidated in the group from September.

LIC Audio AB

During the second quarter, the company LIC Audio AB, whose operations were reported separately within the Getinge Group, was divested. The company develops, sells and conducts service/installation of products for noise distribution, with an emphasis on hearing care. Sales in 2005 amounted to SEK 44 million. The agreed purchase price for the shares of SEK 15 million resulted in a capital gain of SEK 6 million for the quarter after deduction of Group value. LIC Audio AB was consolidated until April.

Getinge South Africa (Pty) Ltd

Infection Control's sales company Getinge South Africa (Pty) Ltd was divested in July 2006. Sales in 2005 amounted to approximately SEK 12 million. The purchase price for the shares totalled about SEK 1 million. The consolidated result from the sale amounted to a loss of approximately SEK 4 million. Getinge South Africa (Pty) Ltd was consolidated until June.

Acquisition of Medical Systems in Brazil

At the end of the period, the business area completed the acquisition 75% of the shares of the Brazilian company Medical Systems, which produces and markets consumables for open heart surgery. The company has sales of approximately SEK 25 million and has 22 employees. At the time of acquisition, the company's assets amounted to SEK 18 million and liabilities to SEK 9 million. The agreed purchase price totalled approximately SEK 16.5 million. Medical Systems is consolidated within the Group effective October 2006.

Definitions

EBIT
EBITA

Operating profit
Operating profit before amortisation of intangible fixed assets identified upon business acquisitions.

Review report

Introduction

We have conducted a review of this interim report for Getinge AB (publ) at 30 September 2006 and the accompanying reports on the income statement and balance sheet, changes in shareholders' equity and changes in cash flow for the nine-month period ending on that date, and a summary of key accounting principles and other supplementary information. It is the company's management that is responsible for accurately preparing and presenting this interim report in accordance with IAS 34. Our responsibility is to state a conclusion on this nine-month report based on our review.

Definition of the work

We have conducted a review in accordance with SÖG 2410 *Review of interim financial information conducted by the company's elected auditor* issued by FAR, the Institute for the Accounting Profession in Sweden. A review consists of interviewing primarily those persons responsible for financial and accounting issues, performing an analytic review and taking general review measures. A review has a different focus and is considerably limited in scope, compared with the focus and scope of an audit in accordance with the Audit Standard in Sweden and generally accepted accounting practices. The review measures that are taken during a review do not allow us to achieve such certainty that we are aware of all important circumstances that would have been identified if an audit had been conducted. The stated conclusion based on a review therefore does not have the same degree of certainty as a stated opinion based on an audit.

Conclusion

Based on our review, no circumstances have emerged to give us reason to believe that this interim report does not provide an accurate presentation in accordance with IAS 34 of the company's financial position at 30 September 2006 and its financial results and cash flow for the nine-month period ending on that date.

Gothenburg, 18 October 2006

DELOITTE AB

Jan Nilsson
Authorised Public Accountant